Opinion|Videos|January 23, 2025
Frontline Treatment Strategies in Non–Clear Cell RCC: Emerging Data and Trials
Panelists discuss the treatment landscape in non–clear cell RCC, highlighting how treatment approaches differ from clear cell RCC, relevant data from frontline settings, and emerging trials of note in this subset of patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do treatment approaches differ in non–clear cell RCC? Please briefly highlight relevant data in the frontline setting and any emerging trials of note.
Advertisement
Related to this article
A personalized ctDNA assay demonstrated 100% specificity but limited sensitivity for detecting recurrence after liver transplantation in HCC and CCA.
The FDA cleared the SpaceOAR Flex System, a hydrogel spacer used during prostate cancer radiotherapy, in a 510(k) supported by the HYDROSPACE trial.
Phase 2 ASPEN-06 data showed higher response rates with evorpacept added to trastuzumab, ramucirumab, and paclitaxel in HER2-positive gastric cancer.
In 62 patients with ICI-naive HPV16-Positive HNSCC, 17.7% experienced grade 3 or 4 treatment-related adverse events.
Ethan B. Ludmir, MD, details which cholangiocarcinoma subsets, by tumor location, may benefit most from neoadjuvant radiation before surgery.
Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.
Clinicians must think a lot about how to make testing and novel treatment advances available for patients globally, according to Chul Kim, MD, MPH.
Daniel C. McFarland, DO, and Yesne Alici, MD, discussed medical aid in dying in cancer care, New York’s safeguards, and the role of psycho-oncology.
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Radiation May Improve Tolerability in Cholangiocarcinoma
2
Defining the Role of Neoadjuvant Radiation in Cholangiocarcinoma
3
Distal Extrahepatic Cholangiocarcinoma May Gain From Neoadjuvant Radiation
4
Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM
5